About the company
Board of directors
The Alzheimer's disease market
The Science behind Pharmasum
DYRK1A - Role in different diseases
Proprietary inhibitors of DYRK1A
Pharmasum Therapeutics AS announces the granting and publishing of its US patent covering composition of matter claims, relating to the Company’s ongoing DYRK1A inhibitor program.